These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 12917088)

  • 1. Reproduction of features of the glucagonoma syndrome with continuous intravenous glucagon infusion as therapy for tumor-induced hypoglycemia.
    Case CC; Vassilopoulou-Sellin R
    Endocr Pract; 2003; 9(1):22-5. PubMed ID: 12917088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Iatrogenic glucagonoma syndrome?].
    Benhamou PY; Reymond JL; Boizel R; Béani JC; Amblard P
    Ann Dermatol Venereol; 1988; 115(6-7):717-9. PubMed ID: 2849361
    [No Abstract]   [Full Text] [Related]  

  • 3. Iatrogenic necrolytic migratory erythema: a case report and review of nonglucagonoma-associated necrolytic migratory erythema.
    Mullans EA; Cohen PR
    J Am Acad Dermatol; 1998 May; 38(5 Pt 2):866-73. PubMed ID: 9591806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of glucagon administration in the diagnosis and treatment of patients with tumor hypoglycemia.
    Hoff AO; Vassilopoulou-Sellin R
    Cancer; 1998 Apr; 82(8):1585-92. PubMed ID: 9554538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-secreting pancreatic islet cell carcinoma, containing insulin and somatostatin, with hypoglycemic attack.
    Yano T; Yamamoto N; Fujimori K; Inamori S; Hayashi H; Mizumoto R
    Am J Gastroenterol; 1982 Jun; 77(6):387-91. PubMed ID: 6124121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of hypoglycemia using glucagon in a patient with an extrapancreatic tumor.
    Samaan NA; Pham FK; Sellin RV; Fernandez JF; Benjamin RS
    Ann Intern Med; 1990 Sep; 113(5):404-6. PubMed ID: 2382921
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of somatostatin in necrolytic migratory erythema of glucagonoma.
    Elsborg L; Glenthøj A
    Acta Med Scand; 1985; 218(2):245-9. PubMed ID: 2865872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Necrolytic migratory erythema associated with glucagonoma syndrome: a case report.
    Dal Coleto CC; de Mello AP; Piquero-Casals J; Lima FR; Vilela MA; Festa-Neto C; Sanches JA
    Rev Hosp Clin Fac Med Sao Paulo; 2001; 56(6):183-8. PubMed ID: 11836542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cystic pancreatic glucagonoma in contact with insulinoma found in a hypoglycemic patient.
    Yagihashi S; Yagihashi N; Nagai K
    Pathol Res Pract; 1992 Aug; 188(6):751-6. PubMed ID: 1437839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic studies and glucagon gel filtration pattern before and after surgery in a case of glucagonoma syndrome.
    von Schenck H; Thorell JI; Berg J; Bojs G; Dymling JF; Hallengren B; Ljungberg O; Tibblin S
    Acta Med Scand; 1979; 205(3):155-62. PubMed ID: 218426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcium reverses octreotide inhibition of insulin and glucagon levels in patients with insulinoma and glucagonoma.
    Thompson CS; O'Dorisio TM; Woltering EA
    Digestion; 1996; 57 Suppl 1():62-8. PubMed ID: 8813473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagonoma syndrome associated with necrolytic migratory erythema.
    Cardoso Filho Fde A; Feitosa RG; Fechine CO; Matos CM; Cardoso AL; Cardoso DL
    Rev Assoc Med Bras (1992); 2015; 61(3):203-6. PubMed ID: 26248239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Necrolytic migratory erythema and glucagonoma rising from pancreatic head.
    Tseng HC; Liu CT; Ho JC; Lin SH
    Pancreatology; 2013; 13(4):455-7. PubMed ID: 23890147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Necrolytic migratory erythema, presenting as candidiasis, due to a pancreatic glucagonoma.
    Katz R; Fischmann AB; Galotto J; Guccio JG; Higgins GA; Ortega LG; West WH; Recant L
    Cancer; 1979 Aug; 44(2):558-63. PubMed ID: 476569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A combined glucagonoma and VIPoma syndrome. First pathologic and clinical report.
    Cavallo-Perin P; De Paoli M; Guiso G; Sapino A; Papotti M; Coda R; Pagano G
    Cancer; 1988 Dec; 62(12):2576-9. PubMed ID: 2847862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagonoma syndrome.
    Bloom SR; Polak JM
    Am J Med; 1987 May; 82(5B):25-36. PubMed ID: 2884877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of necrolytic migratory erythema in glucagonoma syndrome.
    Shepherd ME; Raimer SS; Tyring SK; Smith EB
    J Am Acad Dermatol; 1991 Nov; 25(5 Pt 2):925-8. PubMed ID: 1761771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral amino acid and fatty acid infusion for the treatment of necrolytic migratory erythema in the glucagonoma syndrome.
    Alexander EK; Robinson M; Staniec M; Dluhy RG
    Clin Endocrinol (Oxf); 2002 Dec; 57(6):827-31. PubMed ID: 12460334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The glucagonoma syndrome.
    Shupack JL; Berczeller PH; Stevens DM
    J Dermatol Surg Oncol; 1978 Mar; 4(3):242-7. PubMed ID: 204668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years.
    Kindmark H; Sundin A; Granberg D; Dunder K; Skogseid B; Janson ET; Welin S; Oberg K; Eriksson B
    Med Oncol; 2007; 24(3):330-7. PubMed ID: 17873310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.